Onsdag 3 December | 23:21:11 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-02-13 08:30 Bokslutskommuniké 2025
2025-11-05 - Kvartalsrapport 2025-Q3
2025-08-20 - Kvartalsrapport 2025-Q2
2025-05-15 - X-dag ordinarie utdelning SENZA 0.00 SEK
2025-05-14 - Årsstämma
2025-05-14 - Kvartalsrapport 2025-Q1
2025-02-13 - Bokslutskommuniké 2024
2024-11-08 - Kvartalsrapport 2024-Q3
2024-08-22 - Kvartalsrapport 2024-Q2
2024-05-16 - X-dag ordinarie utdelning SENZA 0.00 SEK
2024-05-15 - Årsstämma
2024-05-15 - Kvartalsrapport 2024-Q1
2024-02-14 - Bokslutskommuniké 2023
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-05 - X-dag ordinarie utdelning SENZA 0.00 SEK
2023-05-04 - Årsstämma
2023-02-16 - Bokslutskommuniké 2022
2022-08-18 - Kvartalsrapport 2022-Q2
2022-05-06 - X-dag ordinarie utdelning SENZA 0.00 SEK
2022-05-05 - Årsstämma
2022-02-11 - Bokslutskommuniké 2021
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-06 - X-dag ordinarie utdelning SENZA 0.00 SEK
2021-05-05 - Årsstämma
2021-02-18 - Bokslutskommuniké 2020
2020-08-20 - Kvartalsrapport 2020-Q2
2020-05-11 - X-dag ordinarie utdelning SENZA 0.00 SEK
2020-05-08 - Årsstämma
2020-02-13 - Bokslutskommuniké 2019
2019-12-18 - Extra Bolagsstämma 2019
2019-08-22 - Kvartalsrapport 2019-Q2
2019-05-16 - X-dag ordinarie utdelning SENZA 0.00 SEK
2019-05-15 - Årsstämma
2019-02-14 - Bokslutskommuniké 2018
2018-08-22 - Kvartalsrapport 2018-Q2
2018-05-09 - X-dag ordinarie utdelning SENZA 0.00 SEK
2018-05-08 - Årsstämma
2018-02-14 - Bokslutskommuniké 2017

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Senzagen är verksamt inom medicinteknik. Bolaget utvecklar och genomför genomiska in vitro-tester, vilket innebär att olika kemikaliers toxikologiska förmåga inte testas på djur utan istället i provrör. Bolaget har utvecklat en teknologisk plattform som används för att studera substansers påverkan producerat av aktörer inom läkemedel, kosmetika- och kemikalieindustrin. Verksamheten bedrivs från huvudkontoret i Lund.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2025-11-12 07:30:00

SenzaGen has received an order from an existing customer in the technology sector. The assignment covers non-animal skin allergy testing using the GARD® platform, with a total value of approximately SEK 2.5 million. The order marks a further step into a relatively new and extensive customer segment, where the company’s experience and expertise in testing chemicals in solid materials have been key factors. The tests will be conducted at the company’s GLP-certified laboratory in Lund, with the majority scheduled for 2025.

The customer is a global leader with innovative consumer products. The tests aim to determine safe dose levels of chemicals in solid materials using GARD®skin Dose-Response, which is specifically optimized for this type of application.

"We are very pleased to have earned the continued trust of this important customer. It demonstrates the breadth of our expertise and the relevance of our unique technology beyond our traditional customer segments. This is our largest order so far this year, and we look forward to supporting the customer’s efforts to deliver safe and allergy-free products," says Peter Nählstedt, CEO and President of SenzaGen.

GARD®skin Dose-Response is a unique non-animal method that provides quantitative data and eliminates the need for animal testing. The method determines at which dose-level substances can be used in a product without causing skin allergies. Based on genomics and machine learning, it can be used as a stand-alone solution without the need for complementary test methods, giving companies across various industries a powerful decision-making tool when developing new products.

A strategic initiative is currently underway to have the method adopted as an OECD standard, which is expected to significantly increase the company’s sales in the coming years.